An early rise in urine N-telopeptide predicts the growth response of normal prepubertal short children to growth hormone therapy.
The effects of growth hormone (GH) therapy on biochemical markers of bone turnover were investigated in 11 short prepubertal children without GH deficiency by measuring serum osteocalcin, a marker for bone formation, and urinary concentrations of pyridinium cross-linked amino acids of collagen (PCL), and the peptide-bound pyridinoline residue N-telopeptide (NT), which are specific markers for bone resorption. GH treatment for three months increased bone turnover in this group of children: urinary PCL concentrations increased from 69 +/- 6.2 to 114 +/- 9.3 nmol/mmol Cr (p < 0.01), and urinary NT levels increased from 512 +/- 65 to 766 +/- 74 pmol BCE/mumol Cr (p = 0.058). Serum osteocalcin concentrations increased from 13.64 +/- 2.57 ng/ml to 26.45 +/- 1.39 ng/ml (p < 0.01). The increment in 12-hour urinary concentrations of PCL was highly correlated with the increment in 12-hour urinary NT levels (r = 0.92, p < 0.01). Stepwise multiple regression analysis revealed that the urinary concentrations of NT after 3 months of GH therapy were the best predictor of growth after 12 months of treatment (r = 0.78, F = 7.9, p = 0.037).
Phillip
M
M
Pediatric Diagnostic and Therapeutic Center, Soroka Medical Center, Ben-Gurion University of the Negev Beer-Sheva, Israel.
Hershkovitz
E
E
Limoni
Y
Y
Leiberman
E
E
Belotserkovsky
O
O
Douvdevani
A
A
Weber
D
D
D001827:Body Height; D001846:Bone Development; D002648:Child; D003094:Collagen / Q000652:urine*; D024042:Collagen Type I; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D015675:Osteocalcin / Q000097:blood; D010455:Peptides / Q000652:urine*
D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D019382:Human Growth Hormone; D003094:Collagen